Literature DB >> 18324367

Contrast agents for MRI.

Emily A Waters1, Samuel A Wickline.   

Abstract

Molecular imaging is a rapidly growing field with the potential to revolutionize cardiovascular medicine by shifting diagnostic focus from functional abnormalities which occur late in a disease process to the biochemical events which precipitate the earliest stages of disease. MRI is a modality well suited to this task as it allows a variety of contrast mechanisms for detection of epitopes of interest, as well as high-resolution anatomical localization and functional information. In this review, we discuss the widerange of available molecular MRI contrast agents and their application to diseases such as atherosclerosis, thrombus imaging, and stem cell tracking, along with opportunities for molecularly targeted drug delivery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18324367     DOI: 10.1007/s00395-008-0711-6

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  25 in total

Review 1.  A review of imaging agent development.

Authors:  Eric D Agdeppa; Mary E Spilker
Journal:  AAPS J       Date:  2009-05-05       Impact factor: 4.009

2.  68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice.

Authors:  Seppo Ylä-Herttula; Juhani Knuuti; Anne Roivainen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

Review 3.  Nanotechnology and its use in imaging and drug delivery (Review).

Authors:  Serjay Sim; Nyet Kui Wong
Journal:  Biomed Rep       Date:  2021-03-05

4.  Gadolinium (III) oxide nanoparticles coated with folic acid-functionalized poly(β-cyclodextrin-co-pentetic acid) as a biocompatible targeted nano-contrast agent for cancer diagnostic: in vitro and in vivo studies.

Authors:  Tohid Mortezazadeh; Elham Gholibegloo; Nader Riyahi Alam; Sadegh Dehghani; Soheila Haghgoo; Hossein Ghanaati; Mehdi Khoobi
Journal:  MAGMA       Date:  2019-02-07       Impact factor: 2.310

5.  Copper-64 Radiopharmaceuticals for Oncologic Imaging.

Authors:  Jason P Holland; Riccardo Ferdani; Carolyn J Anderson; Jason S Lewis
Journal:  PET Clin       Date:  2009-01

Review 6.  Nanoparticle-based monitoring of cell therapy.

Authors:  Chenjie Xu; Luye Mu; Isaac Roes; David Miranda-Nieves; Matthias Nahrendorf; James A Ankrum; Weian Zhao; Jeffrey M Karp
Journal:  Nanotechnology       Date:  2011-11-21       Impact factor: 3.874

7.  Tobacco mosaic virus rods and spheres as supramolecular high-relaxivity MRI contrast agents.

Authors:  Michael A Bruckman; Stephen Hern; Kai Jiang; Chris A Flask; Xin Yu; Nicole F Steinmetz
Journal:  J Mater Chem B       Date:  2013-03-14       Impact factor: 6.331

Review 8.  Liquid perfluorocarbons as contrast agents for ultrasonography and (19)F-MRI.

Authors:  Raquel Díaz-López; Nicolas Tsapis; Elias Fattal
Journal:  Pharm Res       Date:  2009-11-10       Impact factor: 4.200

Review 9.  Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?

Authors:  Catherine Tang; Pamela J Russell; Rosetta Martiniello-Wilks; John E J Rasko; Aparajita Khatri
Journal:  Stem Cells       Date:  2010-09       Impact factor: 6.277

Review 10.  Coronary microvascular resistance: methods for its quantification in humans.

Authors:  Paul Knaapen; Paolo G Camici; Koen M Marques; Robin Nijveldt; Jeroen J Bax; Nico Westerhof; Marco J W Götte; Michael Jerosch-Herold; Heinrich R Schelbert; Adriaan A Lammertsma; Albert C van Rossum
Journal:  Basic Res Cardiol       Date:  2009-05-26       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.